BiotechTube

Sonelokimab

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Arthritis, Psoriatic

Conditions

Arthritis, Psoriatic

Trial Timeline

Nov 13, 2025 → Feb 4, 2028

NCT ID
NCT07223138

About Sonelokimab

Sonelokimab is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Arthritis, Psoriatic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07223138. Target conditions include Arthritis, Psoriatic.

What happened to similar drugs?

20 of 20 similar drugs in Arthritis, Psoriatic were approved

Approved (20) Terminated (0) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Baricitinib + TNF InhibitorEli LillyApproved
✅Ixekizumab + AdalimumabEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07223138Phase 3Recruiting
NCT07007637Phase 3Recruiting
NCT06768671Phase 3Recruiting

Competing Products

20 competing products in Arthritis, Psoriatic

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
LY2127399Eli LillyPhase 3
32
Ixekizumab + PlaceboEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43